Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subasumstat (TAK-981) in Advanced Solid Tumors and Hematologic Malignancies
NCT03648372Phase 2Terminated
- Sponsor
- Takeda
- Start
- Oct 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of subasumstat in solid tumor, hematologic neoplasms, Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) and 4 more (7 arms), sponsored by Takeda. Primary endpoints: Treatment Emergent Adverse Events up to 35.3 months, Treatment Emergent Adverse Events Grade 3 or Higher up to 35.3 months and 2 more. Started Oct 2018; status: terminated.
02
Drugs
subasumstat
03
Conditions
solid tumorhematologic neoplasmsNonsquamous Non-Small Cell Lung Cancer (nsNSCLC)Cervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03648372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648372.